UBS Group
VKTX icon

UBS Group’s Viking Therapeutics VKTX Stock Holding History

UBS Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.8K Buy
+200
New +$6.46K ﹤0.01% 8737
2026
Q1 		– Sell
-39,800
Closed -$1.4M – 11212
2025
Q4 		$1.4M Sell
39,800
-30,200
-43% -$1.07M ﹤0.01% 5286
2025
Q3 		$1.84M Buy
+70,000
New +$2.09M ﹤0.01% 5034
2024
Q3 		– Sell
-26,500
Closed -$1.4M – 10104
2024
Q2 		$1.4M Buy
+26,500
New +$1.74M ﹤0.01% 4107

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

UBS Group's VKTX Position: Q2 2026 in Review

UBS Group reduced its Viking Therapeutics (VKTX) stake by 31% in Q2 2026, selling an estimated $13.3M and leaving 936,055 shares worth $36.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2067.

UBS Group first reported a position in VKTX in Q3 2015 and has held it in 39 quarters since. The position peaked at $43.8M in Q1 2026. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • UBS Group held 936,055 shares of Viking Therapeutics worth $36.5M as of Q2 2026.
  • UBS Group sold 411,417 Viking Therapeutics shares in Q2 2026, an estimated $13.3M.
  • Viking Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2067 holding.
  • UBS Group first reported a position in Viking Therapeutics in Q3 2015 and has held it in 39 quarters since.
  • UBS Group's Viking Therapeutics position peaked at $43.8M in Q1 2026.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.